JAZETA 100mg x 28 tabl
In adult patients with type 2 diabetes mellitus, Jazzeta is indicated to improve glycaemic control:
as monotherapy:
• in patients with inadequate control by diet and exercise alone and for whom metformin is unsuitable due to contraindications or intolerance.
as dual oral therapy in combination with:
• metformin, when diet and exercise, plus metformin alone, do not achieve satisfactory glycemic control.
• a sulfonylurea when diet and exercise, plus the maximum tolerated dose of a sulfonylurea alone, do not achieve satisfactory glycaemic control and when metformin is inappropriate due to contraindications or intolerance.
• a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (e.g., thiazolidinedione), when the use of a PPARγ agonist is appropriate and when diet and exercise plus a PPARγ agonist alone do not achieve satisfactory glycaemic control.
as triple oral therapy in combination with:
• a sulfonylurea and metformin, when diet and exercise, plus dual therapy with these medicinal products, do not achieve satisfactory glycemic control.
• PPARγ agonist and metformin, when the use of a PPARγ agonist is appropriate and when diet and exercise, plus dual therapy with these medicinal products, do not achieve satisfactory glycaemic control.
Jazzeta is also indicated as add-on therapy to insulin (with or without metformin) when diet and exercise, plus a constant dose of insulin, do not achieve satisfactory glycaemic control.
Composition:
Sitagliptin (as sitagliptin hydrochloride monohydrate)
